Tevogen Inc.
As of Oct 22, 2026, Tevogen is in Stage 1, the basing phase, now in week 5 (since Sep 23, 2026). It closed at $6.81, 79.5% below its 52-week high and below its 200-day average, which is falling.
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is TVGN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
TVGN among Biotechnology474th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …474 | TVGN | Stage 1 · wk 5 | 11 | −12.8% |
Tevogen: quick answers
What stage is Tevogen in?
As of Oct 22, 2026, Tevogen (TVGN) is in Stage 1, the basing phase. It entered Stage 1 on Sep 23, 2026 and is in week 5. What the four stages mean
Is Tevogen in an uptrend?
Not yet. Tevogen is in Stage 1, a base that can come before an uptrend. It trades 20.2% below its 200-day average, which is falling.
How far is Tevogen from its 52-week high?
Tevogen closed at $6.81 on Oct 22, 2026, 79.5% below its 52-week high of $33.30. Its 52-week low is $3.89.
How has Tevogen performed over the past year?
As of Oct 22, 2026, Tevogen is down 79.8% over the past year and down 62.6% so far in 2026.
Which sector and industry is Tevogen in?
Tevogen is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B. It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.